PKR Inhibitor (CAS 608512-97-6)

The PKR(RNA-dependent protein kinase) inhibitor is a compound derived from imidazolo-oxindole that has demonstrated the ability to inhibit the autophosphorylation of PKR induced by RNA and restore PKR-dependent translation. PKR is an interferon-induced serine/threonine protein responsible for phosphorylating the alpha subunit of the eukaryotic initiation factor 2. It plays a role in regulating cytokine gene expression stimulated by Epstein-Barr virus′s latent membrane protein 1 (LMP). Studies have indicated that the PKR inhibitor can effectively suppress the activities of caspase-3 and caspase-8, thereby preventing the increase in pT(451)-PKR and pS(194)-FADD levels within the nuclei of SH-SY5Y cells. Furthermore, PKR inhibitor has shown potential in protecting cells against cellular damage induced by endoplasmic reticulum (ER) stress. PKR inhibitors are specifically designed molecules used to hinder the activity of PKR, an enzyme involved in regulating mRNA translation into proteins. This enzyme plays a vital role in various cellular processes, including apoptosis, cell cycle progression, and the production of inflammatory cytokines. Scientists employ PKR inhibitors in scientific research to investigate the functions and mechanisms of PKR in these processes. PKR inhibitor inhibitors find wide-ranging applications in both in vivo and in vitro studies. In vivo applications involve examining the impact of PKR inhibitors on apoptosis, cell cycle progression, and inflammatory cytokine production. In vitro applications focus on investigating the effects of PKR inhibitor inhibitors on protein synthesis and cellular signaling. The precise mechanism of action underlying PKR inhibitor inhibitors is not yet fully understood. However, it is believed that these inhibitors bind to the active site of the PKR enzyme, effectively blocking its activity. This interaction prevents the enzyme from phosphorylating its substrates and subsequently inhibits the activation of downstream signaling pathways.